Case-Control Viramune (Nevirapine) Toxicogenomics Study
Public ClinicalTrials.gov record NCT00310843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity Within the First 8 Weeks of Nevirapine Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.
Study identification
- NCT ID
- NCT00310843
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 889 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2006 (Type not available)
- Primary completion
- Sep 2008 (Actual)
- Completion
- Not listed
- Last update posted
- Aug 1, 2013
Started 2006
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1100.1452.01006 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1100.1452.01013 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 1100.1452.99999 Boehringer Ingelheim Investigational Site | Baltimore | Connecticut | — | — |
| 1100.1452.01011 Boehringer Ingelheim Investigational Site | New Haven | Connecticut | — | — |
| 1100.1452.01003 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1100.1452.01002 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 1100.1452.01014 Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | — | — |
| 1100.1452.01015 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1100.1452.01016 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1100.1452.01012 Boehringer Ingelheim Investigational Site | Chapel Hill | North Carolina | — | — |
| 1100.1452.01001 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 1100.1452.01004 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00310843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 1, 2013 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00310843 live on ClinicalTrials.gov.